Genetics, Gene Expression, and Targeted Therapies in Chronic Lymphocytic Leukemia

E-ISSN： 1873-5592|7|10|1313-1327

ISSN： 1389-4501

Source： Current Drug Targets, Vol.7, Iss.10, 2006-10, pp. : 1313-1327

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia

Current Medicinal Chemistry, Vol. 19, Iss. 31, 2012-11 ,pp. : 5294-5318

Bentham Science Publishers

Access to resources Recommend Favorite

Pentostatin in chronic lymphocytic leukemia

By Sauter Craig Lamanna Nicole Weiss Mark A

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 9, 2008-09 ,pp. : 1217-1222

Informa Healthcare

Access to resources Recommend Favorite

Bendamustine for treatment of chronic lymphocytic leukemia

By Chang Julie Elizabeth Kahl Brad Steven

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1495-1505

Informa Healthcare

Access to resources Recommend Favorite

Lenalidomide in lymphomas and chronic lymphocytic leukemia

By Wiernik Peter H

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 4, 2013-03 ,pp. : 475-488

Informa Healthcare

Access to resources Recommend Favorite

Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)

Current Cancer Drug Targets, Vol. 9, Iss. 4, 2009-06 ,pp. : 510-518

Bentham Science Publishers

Access to resources Recommend Favorite